CDKN2B and urinary bladder cancer: In this study, we identified that overexpression of hsa-miR-429 is a novel contributor to the down-regulation of CDKN2B in bladder cancer, suggesting that post-transcriptional inhibition plays roles in repressing CDKN2B expression.